Shopping Cart
- Remove All
Your shopping cart is currently empty
Rosuvastatin calcium (ZD4522) , a selective and competitive inhibitor of hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, has antilipidemic activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $35 | In Stock | |
| 50 mg | $47 | In Stock | |
| 100 mg | $84 | In Stock | |
| 500 mg | $216 | In Stock |
| Description | Rosuvastatin calcium (ZD4522) , a selective and competitive inhibitor of hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, has antilipidemic activity. |
| Targets&IC50 | HMG-CoA:11 nM |
| In vitro | In streptozotocin-induced diabetic rats, daily administration of Rosuvastatin (20 mg/kg) significantly reduces the content of very low-density lipoprotein (VLDL) within the body. Similarly, in male beagles with normal cholesterol levels, Rosuvastatin (3 mg/kg) effectively lowers the concentration of cholesterol in the plasma. |
| In vivo | In isolated rat hepatocytes (IC50=1.12 nM), Rosuvastatin acts as a high-affinity substrate for OATP-C, inhibiting cholesterol synthesis. Additionally, in endothelial cells, Rosuvastatin suppresses the expression and protein levels of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA by inhibiting the c-Jun N-terminal kinase and nuclear factor-kB. |
| Synonyms | ZD 4522 Calcium, Rosuvastatin hemicalcium |
| Molecular Weight | 1001.14 |
| Formula | 2(C22H27FN3O6S)Ca |
| Cas No. | 147098-20-2 |
| Smiles | [Ca++].CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1.CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1 |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 123 mg/mL (122.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (4 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.